دورية أكاديمية
أعرض في EDS

Therapeutic potential of highly functional codon-optimized microutrophin for muscle-specific expression.

التفاصيل البيبلوغرافية
العنوان: Therapeutic potential of highly functional codon-optimized microutrophin for muscle-specific expression.
المؤلفون: Starikova AV; Laboratory of Modeling and Gene Therapy of Hereditary Diseases, Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russia, 119334., Skopenkova VV; Laboratory of Modeling and Gene Therapy of Hereditary Diseases, Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russia, 119334.; Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russia, 119334., Polikarpova AV; Laboratory of Modeling and Gene Therapy of Hereditary Diseases, Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russia, 119334., Reshetov DA; Research Centre for Genetic Medicine, Moscow, Russia, 117292., Vassilieva SG; Laboratory of Modeling and Gene Therapy of Hereditary Diseases, Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russia, 119334., Velyaev OA; Laboratory of Modeling and Gene Therapy of Hereditary Diseases, Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russia, 119334., Shmidt AA; Laboratory of Modeling and Gene Therapy of Hereditary Diseases, Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russia, 119334.; Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russia, 119334., Savchenko IM; Laboratory of Modeling and Gene Therapy of Hereditary Diseases, Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russia, 119334., Soldatov VO; Department of Pharmacology and Clinical Pharmacology, Belgorod State National Research University, Belgorod, Russia, 308007.; Institute of Gene Biology, Core Facility Centre, Russian Academy of Sciences, Moscow, Russia, 119334., Egorova TV; Laboratory of Modeling and Gene Therapy of Hereditary Diseases, Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russia, 119334. egorovatv@genebiology.ru.; Marlin Biotech LLC, Sochi, Russia, 354340. egorovatv@genebiology.ru., Bardina MV; Laboratory of Modeling and Gene Therapy of Hereditary Diseases, Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russia, 119334.; Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russia, 119334.; Marlin Biotech LLC, Sochi, Russia, 354340.
المصدر: Scientific reports [Sci Rep] 2022 Jan 17; Vol. 12 (1), pp. 848. Date of Electronic Publication: 2022 Jan 17.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Codon*, Genetic Therapy/*methods , Muscular Dystrophy, Duchenne/*therapy , Utrophin/*therapeutic use, Animals ; Creatine Kinase ; Gene Expression ; Humans ; Injections, Intramuscular ; Mice ; Mice, Inbred mdx ; Muscles/metabolism ; Phenotype ; Utrophin/administration & dosage ; Utrophin/genetics ; Utrophin/metabolism
مستخلص: High expectations have been set on gene therapy with an AAV-delivered shortened version of dystrophin (µDys) for Duchenne muscular dystrophy (DMD), with several drug candidates currently undergoing clinical trials. Safety concerns with this therapeutic approach include the immune response to introduced dystrophin antigens observed in some DMD patients. Recent reports highlighted microutrophin (µUtrn) as a less immunogenic functional dystrophin substitute for gene therapy. In the current study, we created a human codon-optimized µUtrn which was subjected to side-by-side characterization with previously reported mouse and human µUtrn sequences after rAAV9 intramuscular injections in mdx mice. Long-term studies with systemic delivery of rAAV9-µUtrn demonstrated robust transgene expression in muscles, with localization to the sarcolemma, functional improvement of muscle performance, decreased creatine kinase levels, and lower immunogenicity as compared to µDys. An extensive toxicity study in wild-type rats did not reveal adverse changes associated with high-dose rAAV9 administration and human codon-optimized µUtrn overexpression. Furthermore, we verified that muscle-specific promoters MHCK7 and SPc5-12 drive a sufficient level of rAAV9-µUtrn expression to ameliorate the dystrophic phenotype in mdx mice. Our results provide ground for taking human codon-optimized µUtrn combined with muscle-specific promoters into clinical development as safe and efficient gene therapy for DMD.
(© 2022. The Author(s).)
References: Muscle Nerve. 2013 Jul;48(1):21-6. (PMID: 23716304)
Clin Immunol. 2001 Feb;98(2):235-43. (PMID: 11161980)
Nat Med. 1998 Dec;4(12):1441-4. (PMID: 9846586)
Hum Gene Ther Clin Dev. 2015 Mar;26(1):57-69. (PMID: 25710459)
Neuromuscul Disord. 1998 Aug;8(6):351-61. (PMID: 9713851)
Hum Gene Ther. 2018 Mar;29(3):285-298. (PMID: 29378426)
Methods Mol Biol. 2017;1641:101-114. (PMID: 28748459)
Gene Ther. 2003 May;10(9):750-7. (PMID: 12704413)
Mol Ther. 2008 Sep;16(9):1539-45. (PMID: 18665159)
Histochem J. 1993 Aug;25(8):554-61. (PMID: 8407365)
Nat Med. 2002 Mar;8(3):253-61. (PMID: 11875496)
Mol Ther Methods Clin Dev. 2017 Jul 27;6:216-230. (PMID: 28932757)
Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13856-60. (PMID: 15365169)
Nat Biotechnol. 1999 Mar;17(3):241-5. (PMID: 10096290)
J Muscle Res Cell Motil. 2001;22(5):467-75. (PMID: 11964072)
Mol Med Rep. 2019 May;19(5):4377-4387. (PMID: 30942461)
Neuromuscul Disord. 2001 Nov;11(8):713-21. (PMID: 11595513)
PLoS Med. 2009 May 26;6(5):e1000083. (PMID: 19478831)
Nat Med. 2019 Oct;25(10):1505-1511. (PMID: 31591596)
Methods Mol Biol. 2011;709:21-37. (PMID: 21194019)
PLoS Genet. 2020 Nov 11;16(11):e1009179. (PMID: 33175853)
Hum Gene Ther Methods. 2012 Feb;23(1):18-28. (PMID: 22428977)
Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt A):1172-1182. (PMID: 29408646)
Acta Naturae. 2021 Jan-Mar;13(1):47-58. (PMID: 33959386)
PLoS One. 2019 Jan 30;14(1):e0211384. (PMID: 30699165)
N Engl J Med. 2010 Oct 7;363(15):1429-37. (PMID: 20925545)
Mol Ther. 2008 Nov;16(11):1825-32. (PMID: 18766174)
Mol Ther. 2020 Mar 4;28(3):747-757. (PMID: 31982038)
PLoS One. 2011;6(10):e26169. (PMID: 22028826)
Mol Ther. 2007 Feb;15(2):320-9. (PMID: 17235310)
Mol Ther Methods Clin Dev. 2016 May 11;3:16035. (PMID: 27226971)
BMC Bioinformatics. 2008 Nov 15;9:482. (PMID: 19014601)
PLoS One. 2011 May 06;6(5):e19189. (PMID: 21573153)
Mol Ther. 2010 Jan;18(1):109-17. (PMID: 19904237)
Gene Ther. 2008 Nov;15(22):1489-99. (PMID: 18563184)
Mol Ther Methods Clin Dev. 2018 Oct 16;11:92-105. (PMID: 30417024)
Mol Ther Methods Clin Dev. 2017 Jul 24;6:143-158. (PMID: 28932756)
Physiol Genomics. 2000 Sep 08;3(3):133-44. (PMID: 11015608)
J Vis Exp. 2014 Mar 27;(85):. (PMID: 24747372)
Mol Ther. 2018 Oct 3;26(10):2337-2356. (PMID: 30093306)
Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):762-7. (PMID: 21187385)
Am J Physiol Cell Physiol. 2007 Sep;293(3):C985-92. (PMID: 17567750)
Dis Model Mech. 2019 Apr 25;12(4):. (PMID: 31028078)
PLoS One. 2007 Aug 22;2(8):e774. (PMID: 17712422)
Front Immunol. 2020 Apr 17;11:670. (PMID: 32362898)
Exp Cell Res. 2020 Jul 15;392(2):112033. (PMID: 32360435)
Hum Gene Ther. 2011 Oct;22(10):1239-47. (PMID: 21609134)
J Neuroimmunol. 2004 Mar;148(1-2):97-105. (PMID: 14975590)
Hum Gene Ther. 2017 May;28(5):428-436. (PMID: 27485975)
Gene Ther. 1999 Jun;6(6):973-85. (PMID: 10455399)
J Mol Evol. 1983;19(3-4):214-8. (PMID: 6887263)
معلومات مُعتمدة: GRNTIS5/42610 The Foundation for Assistance to Small Innovative Enterprises in Science and Technology; GRNTIS5/42610 The Foundation for Assistance to Small Innovative Enterprises in Science and Technology
المشرفين على المادة: 0 (Codon)
0 (Utrophin)
EC 2.7.3.2 (Creatine Kinase)
تواريخ الأحداث: Date Created: 20220118 Date Completed: 20220301 Latest Revision: 20220301
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8764061
DOI: 10.1038/s41598-022-04892-x
PMID: 35039573
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-022-04892-x